Transgene SA (EPA: TNG)
France
· Delayed Price · Currency is EUR | Market Cap | 149.15M |
| Revenue (ttm) | 7.90M |
| Net Income (ttm) | -22.33M |
| Shares Out | 131.99M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,265 |
| Open | 1.128 |
| Previous Close | 1.120 |
| Day's Range | 1.120 - 1.130 |
| 52-Week Range | 0.985 - 1.860 |
| Beta | 0.78 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 24, 2024 |
About Transgene
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; an... [Read more]
Financial Performance
In 2023, Cellectis's revenue was $9.19 million, a decrease of -64.26% compared to the previous year's $25.72 million. Losses were -$101.06 million, -4.79% less than in 2022.
Financial StatementsNews
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
STRASBOURG, France--(BUSINESS WIRE)---- $TNG--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced tha...
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022
Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and Bi...
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
STRASBOURG, France--(BUSINESS WIRE)-- #HBV--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces...
R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
STRASBOURG, France--(BUSINESS WIRE)-- #HBV--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, wil...
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
STRASBOURG, France--(BUSINESS WIRE)---- $TNG--New positive TG6002 Phase I data confirm the mechanism of action of this oncolytic virus when administered intravenously.